BR112014004302A2 - conjugado, composição farmacêutica, processo para preparar um conjugado, métodos para inibir a proliferação de uma célula cancerosa, para tratar um distúrbio, e para tratar um paciente - Google Patents
conjugado, composição farmacêutica, processo para preparar um conjugado, métodos para inibir a proliferação de uma célula cancerosa, para tratar um distúrbio, e para tratar um pacienteInfo
- Publication number
- BR112014004302A2 BR112014004302A2 BR112014004302A BR112014004302A BR112014004302A2 BR 112014004302 A2 BR112014004302 A2 BR 112014004302A2 BR 112014004302 A BR112014004302 A BR 112014004302A BR 112014004302 A BR112014004302 A BR 112014004302A BR 112014004302 A2 BR112014004302 A2 BR 112014004302A2
- Authority
- BR
- Brazil
- Prior art keywords
- conjugate
- treating
- disorder
- patient
- preparing
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000035755 proliferation Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| VN201102222 | 2011-08-25 | ||
| PCT/US2012/027317 WO2013028233A1 (en) | 2011-08-25 | 2012-03-01 | Peg-interferon lambda 1 conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014004302A2 true BR112014004302A2 (pt) | 2017-06-20 |
Family
ID=47746747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014004302A BR112014004302A2 (pt) | 2011-08-25 | 2012-03-01 | conjugado, composição farmacêutica, processo para preparar um conjugado, métodos para inibir a proliferação de uma célula cancerosa, para tratar um distúrbio, e para tratar um paciente |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2748328A4 (https=) |
| JP (1) | JP2014525939A (https=) |
| CN (1) | CN103228792A (https=) |
| AU (1) | AU2012299423A1 (https=) |
| BR (1) | BR112014004302A2 (https=) |
| CA (1) | CA2846092A1 (https=) |
| RU (1) | RU2014111179A (https=) |
| WO (1) | WO2013028233A1 (https=) |
| ZA (1) | ZA201401159B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7674628B2 (ja) | 2016-02-19 | 2025-05-12 | イーアイティー・ファーマ・インコーポレイテッド | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 |
| ES3015227T3 (en) | 2017-03-16 | 2025-04-30 | Evangelos Andreakos | Use of lambda interferons in the treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder |
| RU2678332C1 (ru) * | 2017-09-08 | 2019-01-28 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") | Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения |
| CN112245570A (zh) | 2019-07-22 | 2021-01-22 | 厦门特宝生物工程股份有限公司 | 一种基于干扰素的疾病治疗方法 |
| JP2024504341A (ja) | 2021-01-21 | 2024-01-31 | シャーメン アモイトップ バイオテック カンパニー， リミテッド | 癌を治療するためのインターフェロンベースの方法及び組合せ医薬 |
| EP4282426A4 (en) | 2021-01-21 | 2024-11-27 | Xiamen Amoytop Biotech Co., Ltd. | Method and pharmaceutical combination for preventing cancer recurrence |
| WO2024121424A1 (en) | 2022-12-09 | 2024-06-13 | Daniel Zagury | Composite aids vaccine generating anti-hiv specific neutralizing antibodies and/or anti-hiv cytotoxic t cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| CN1176137C (zh) * | 2002-01-15 | 2004-11-17 | 泛亚生物技术有限公司 | 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用 |
| CN1927388B (zh) * | 2004-09-10 | 2011-02-02 | 北京金迪克生物技术研究所 | 含有人干扰素的药物组合物 |
| WO2006133089A2 (en) * | 2005-06-03 | 2006-12-14 | Ambrx, Inc. | Improved human interferon molecules and their uses |
| WO2007041713A1 (en) * | 2005-10-04 | 2007-04-12 | Zymogenetics, Inc. | Production and purification of il-29 |
| CN101002942B (zh) * | 2007-01-08 | 2010-07-21 | 湖南大学 | 一种peg化脂质体纳米颗粒 |
| JP2011522834A (ja) * | 2008-06-05 | 2011-08-04 | ザイモジェネティクス リミテッド ライアビリティ カンパニー | Ｃ型肝炎の治療のためのペグ化ｉｉｉ型インターフェロンの使用 |
-
2012
- 2012-03-01 BR BR112014004302A patent/BR112014004302A2/pt not_active IP Right Cessation
- 2012-03-01 RU RU2014111179/10A patent/RU2014111179A/ru not_active Application Discontinuation
- 2012-03-01 JP JP2014527142A patent/JP2014525939A/ja not_active Withdrawn
- 2012-03-01 CA CA2846092A patent/CA2846092A1/en not_active Abandoned
- 2012-03-01 EP EP12825651.8A patent/EP2748328A4/en not_active Withdrawn
- 2012-03-01 CN CN2012800033678A patent/CN103228792A/zh active Pending
- 2012-03-01 AU AU2012299423A patent/AU2012299423A1/en not_active Abandoned
- 2012-03-01 WO PCT/US2012/027317 patent/WO2013028233A1/en not_active Ceased
-
2014
- 2014-02-14 ZA ZA2014/01159A patent/ZA201401159B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012299423A1 (en) | 2014-03-06 |
| ZA201401159B (en) | 2015-04-29 |
| JP2014525939A (ja) | 2014-10-02 |
| CN103228792A (zh) | 2013-07-31 |
| RU2014111179A (ru) | 2015-09-27 |
| EP2748328A1 (en) | 2014-07-02 |
| WO2013028233A1 (en) | 2013-02-28 |
| EP2748328A4 (en) | 2015-03-04 |
| CA2846092A1 (en) | 2013-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014015003A2 (pt) | composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral | |
| BR112013031819A2 (pt) | suporte polimérico, composição farmacêutica, composto, métodos de tratar um distúrbio, e, de preparar um suporte | |
| PL2818482T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu | |
| PL2824114T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu | |
| BR112015000441A2 (pt) | imunoconjugados, formulação farmacêutica e método de tratamento e método para inbir a proliferação de uma célula positiva para cd22 | |
| PL2672966T3 (pl) | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania | |
| BR112015000437A2 (pt) | imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula | |
| BR112015004489A2 (pt) | composto, composição farmacêutica, e, métodos para tratar um distúrbio proliferativo e para sintetizar um composto | |
| BR112012018947A2 (pt) | composição farmacêutica para tratamento e\ou prevenção do cancêr | |
| BR112013004858A2 (pt) | derivados de 4-{[(piridin-3-il-metil) amnocarbonil]amino}benzeno-sulfona como inibidores de nampt para terapia para terapia de doenças tal como câncer | |
| BR112015007061A2 (pt) | composto, composição farmacêutica e método para tratar uma condição ou distúrbio dependente de apkc em um paciente | |
| BR112012026843A2 (pt) | composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv | |
| PT2434891T (pt) | Métodos para tratamento de cancro e afeções não neoplásicas | |
| BR112014032105A2 (pt) | método para o tratamento de câncer | |
| BR112015010501A2 (pt) | composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada | |
| BR112013014583A2 (pt) | composição farmacêutica, e, métodos para o tratamento de inflamação, para o tratamento da dor, e para preparar 3-metanossulfonilpropionitrila | |
| BR112013007276A2 (pt) | composição farmacêutica, processo para preparar uma composição farmacêutica, uso da coposição farmacêutica e método para tratar sobrecarga crônica de ferro | |
| BR112014003997A2 (pt) | composto, método para inibição da atividade de pak1 em uma célula e paciente, método para o tratamento ou melhoria da gravidade do câncer ou de um distúrbio hiperproliferativo em um paciente, utilização do composto e composição | |
| BR112014032053A2 (pt) | composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção | |
| BR112013024169A2 (pt) | método para o tratamento e prevenção da doença de parkinson | |
| BR112014031896A2 (pt) | composto, composição farmacêutica, e, método para o tratamento de um distúrbio | |
| BR112014004302A2 (pt) | conjugado, composição farmacêutica, processo para preparar um conjugado, métodos para inibir a proliferação de uma célula cancerosa, para tratar um distúrbio, e para tratar um paciente | |
| BR112012020585A2 (pt) | composto, composição farmacêutica e método de tratamento de um distúrbio mediado por tirosina quinase | |
| BR112013033078A2 (pt) | partícula, composição farmacêutica, conjunto para o tratamento do câncer e método para o tratamento do câncer em um paciente | |
| BR112015002493A2 (pt) | composto , composição farmacêutica , método para o tratamento do câncer , processo para a preparação de uma composição farmacêutica , conjunto , utilização de um composto e invenção. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: dismissal - article 86 of industrial property law | ||
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |